A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Sponsor: GSK/Tesaro

Participating sites:

  • UZ Leuven, Leuven
  • AZ Sint-Jan Brugge, Brugge
  • CHU St. Pierre, Bruxelles
  • AZ Klina, Brasschaat